Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

Aduro Biotech logo

About Aduro Biotech Stock (NASDAQ:ADRO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.28
$14.60
52-Week Range
N/A
Volume
171,500 shs
Average Volume
162,237 shs
Market Capitalization
$236.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

ADRO Stock News Headlines

Aduro Clean Technologies Inc.
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.
ACTHD Aduro Clean Technologies Inc.
Aduro Clean Technologies Inc Ordinary Shares
PT Adaro Energy Indonesia Tbk
PT Adaro Energy Indonesia Tbk ADRO
See More Headlines

ADRO Stock Analysis - Frequently Asked Questions

Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.

Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
5/04/2020
Today
4/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADRO
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-82,370,000.00
Net Margins
-230.92%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$17.26 million
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$236.61 million
Optionable
Optionable
Beta
0.40
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ADRO) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners